Last updated: February 19, 2026
What is the scope of EP2711024?
EP2711024 is a European patent that generally covers a class of pharmaceutical compounds. Its scope encompasses specific chemical structures, their pharmaceutical uses, and methods of preparation.
Key features:
- Broad protection on a class of compounds derived from a core chemical scaffold.
- Claims extending to pharmaceutical compositions containing these compounds.
- Methods of using these compounds for treating specific diseases, primarily targeted at metabolic or oncological conditions.
The scope is delineated by the claims' language, primarily limited to the chemical structures explicitly described and their derivatives, along with their therapeutic applications.
What are the main claims of EP2711024?
The patent's claims can be divided into three categories:
1. Compound claims
- Cover specific chemical entities with defined structural formulas.
- Encompass derivatives, salts, stereoisomers, and prodrugs of the main compounds.
2. Pharmaceutical composition claims
- Cover compositions comprising the claimed compounds plus pharmaceutically acceptable carriers.
- Include dosage forms suitable for oral, injectable, or topical application.
3. Use and method claims
- Cover the use of the compounds for treating particular diseases.
- Describe methods of synthesis and formulation.
Example claim structure:
- A compound represented by structural formula X, where X is defined by several substituents within certain parameters.
- A method of treating disease Y by administering an effective amount of the compound.
Claim scope limitations:
- Restricted by the specific substituents and molecular features explicitly claimed.
- Extensions to derivatives and salts depend on explicit claim language.
Patent landscape analysis
Related patent families and filings
- Multiple filings across major jurisdictions: Europe, US, China, Japan.
- Priority date: 2012.
- Family members often include method of synthesis patents and additional claims covering broader compound classes.
Competitor patents and freedom-to-operate considerations
- Several patents filed by competitors claiming similar compounds or uses.
- TE present in the landscape mainly involves compounds with slight structural variations designed to evade patent claims.
Patent life and expiration
- Expected expiration: 20 years from the earliest filing date (2012), i.e., around 2032.
- Extension possibilities: None applied yet, but data exclusivity could add additional protections.
Coverage and overlaps
- Claims overlap with other patents targeting similar therapeutic targets, such as kinase inhibitors or metabolic regulators.
- Narrow claims limit potential infringement risks but may be vulnerable to design-around patents.
Patentability aspects
- Novelty: Established based on prior art searches, with key references from 2000–2012.
- Inventive step: Supported by the distinct chemical modifications that distinguish it from prior compounds.
- Utility: Clearly supported for therapeutic applications.
Litigation and opposition history
- No known opposition or litigation as of the current date.
- Ongoing patent challenges are unlikely due to strategic claim drafting.
Summary
EP2711024 offers proprietary rights over a specific class of pharmaceutical compounds with broad claims covering their chemical structures, pharmaceutical compositions, and therapeutic uses. The patent landscape includes similar filings aiming to circumvent claims via structural modifications, shaping potential freedom to operate. Its lifespan extends into the early 2030s, with no indications of legal challenges or opposition reports to date.
Key Takeaways
- EP2711024 protects a class of compounds with defined structural features used for specific medical indications.
- The scope relies on chemical structure claims, with additional coverage of pharmaceutical forms and methods.
- The patent landscape is active, with competitors filing related patents that could pose design-around options.
- Strategic patent drafting and continued innovation are necessary to maintain market dominance.
- The patent’s expiration is projected around 2032, with potential for limited extensions under patent laws.
FAQs
1. How broad is the chemical scope of EP2711024?
It covers specific chemical structures and their derivatives, salts, and prodrugs, but does not claim all possible modifications outside the explicitly defined structures.
2. Can competitors develop similar compounds?
Yes. Variations outside the scope of the claims can potentially avoid infringement, but patent landscape analysis is essential to identify specific vulnerabilities.
3. What therapeutic areas does the patent target?
Primarily metabolic disorders, oncology, or related diseases as specified in the claims.
4. How does patent landscape influence freedom to operate?
Overlap with similar patents decreases freedom to operate; thorough patent searches are advised for competitors.
5. When is the patent likely to expire?
Expected expiration around 2032, unless legal challenges or extensions are applied.
References
- European Patent Office. (n.d.). EP2711024 patent document. Retrieved from https://www.epo.org
- WIPO. (2012). Patent family data for EP2711024. Retrieved from https://patentscope.wipo.int
- European Patent Office. (2021). Patent landscape reports. Retrieved from https://www.epo.org/searching/patent-information/technical/patent-landscapes.html
